PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31383729-10 2019 The cannabinoid receptor 2 (CB2) agonist, JWH-015, impaired monocyte IL-1beta production similar to that of THC, suggesting that THC acts, in part, through CB2. JHW 015 42-49 cannabinoid receptor 2 Homo sapiens 4-26 31383729-10 2019 The cannabinoid receptor 2 (CB2) agonist, JWH-015, impaired monocyte IL-1beta production similar to that of THC, suggesting that THC acts, in part, through CB2. JHW 015 42-49 cannabinoid receptor 2 Homo sapiens 28-31 31383729-10 2019 The cannabinoid receptor 2 (CB2) agonist, JWH-015, impaired monocyte IL-1beta production similar to that of THC, suggesting that THC acts, in part, through CB2. JHW 015 42-49 cannabinoid receptor 2 Homo sapiens 156-159 23706402-5 2013 The cannabinoid receptor 2 (CB2) receptor-selective agonist JWH-015 significantly reduced colitis scores following cytokine incubation, as evidenced by a reduction in mucosal crypt and luminal epithelial damage and lymphocyte density in the lamina propria. JHW 015 60-67 cannabinoid receptor 2 Homo sapiens 4-26 31139184-0 2019 Cannabinoid Receptor 2 Agonist JWH-015 Inhibits Interleukin-1beta-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts and in Adjuvant Induced Arthritis Rat via Glucocorticoid Receptor. JHW 015 31-38 cannabinoid receptor 2 Homo sapiens 0-22 31139184-2 2019 In the present study, we evaluated the efficacy of cannabinoid receptor 2 (CB2) agonist JWH-015 using RA synovial fibroblasts (RASFs) obtained from patients diagnosed with RA and in a rat adjuvant-induced arthritis (AIA) model of RA. JHW 015 88-95 cannabinoid receptor 2 Homo sapiens 51-73 31139184-2 2019 In the present study, we evaluated the efficacy of cannabinoid receptor 2 (CB2) agonist JWH-015 using RA synovial fibroblasts (RASFs) obtained from patients diagnosed with RA and in a rat adjuvant-induced arthritis (AIA) model of RA. JHW 015 88-95 cannabinoid receptor 2 Homo sapiens 75-78 23706402-5 2013 The cannabinoid receptor 2 (CB2) receptor-selective agonist JWH-015 significantly reduced colitis scores following cytokine incubation, as evidenced by a reduction in mucosal crypt and luminal epithelial damage and lymphocyte density in the lamina propria. JHW 015 60-67 cannabinoid receptor 2 Homo sapiens 28-31 23706402-6 2013 The effect of JWH-015 was reversed in the presence of the CB2 receptor inverse agonist JTE-907. JHW 015 14-21 cannabinoid receptor 2 Homo sapiens 58-61 22903605-10 2013 The systemic administration of a CB(2) agonist, JWH015, for 7 days significantly attenuated bone remodeling, assuaged spontaneous pain, and decreased primary tumor burden. JHW 015 48-54 cannabinoid receptor 2 Homo sapiens 33-38 19547718-10 2009 The CB1/CB2 receptor agonist, CP55,940, and the CB2 receptor agonist, JWH015 significantly protected RPE cells from oxidative damage. JHW 015 70-76 cannabinoid receptor 2 Homo sapiens 48-51 19858202-3 2009 In human primary and Jurkat T lymphocytes, activation of CB1 by R(+)-methanandamide, CB2 by JWH015, and both by Delta9-tetrahydrocannabinol induced a short decrease in cyclic AMP lasting less than 1 h. However, this decrease was followed by a massive (up to 10-fold) and sustained (at least up to 48 h) increase in cyclic AMP. JHW 015 92-98 cannabinoid receptor 2 Homo sapiens 85-88 17185040-0 2007 CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. JHW 015 34-41 cannabinoid receptor 2 Homo sapiens 0-3 18178718-0 2008 CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. JHW 015 33-40 cannabinoid receptor 2 Homo sapiens 0-3 18178718-3 2008 Human monocytes treated with the CB2 agonist JWH-015 for 12-18 h showed significantly reduced migration to chemokines CCL2 and CCL3, associated with reduced mRNA and surface expression of their receptors CCR2 and CCR1. JHW 015 45-52 cannabinoid receptor 2 Homo sapiens 33-36 18178718-6 2008 The CB2-selective antagonist SR-144528, but not the CB1 antagonist SR-147778, reversed JWH-015-induced actions, whereas the CB2 agonist JWH-133 mimicked the effects of JWH-015. JHW 015 87-94 cannabinoid receptor 2 Homo sapiens 4-7 18178718-6 2008 The CB2-selective antagonist SR-144528, but not the CB1 antagonist SR-147778, reversed JWH-015-induced actions, whereas the CB2 agonist JWH-133 mimicked the effects of JWH-015. JHW 015 168-175 cannabinoid receptor 2 Homo sapiens 124-127 17679938-13 2007 Western blot analysis revealed that JWH015 also diminished the level of phosphorylated cofilin in TM cells and this effect of JWH015 was antagonized by SR144528 but not by SR141716A, indicating a CB2 receptor-mediated activation of cofilin. JHW 015 36-42 cannabinoid receptor 2 Homo sapiens 196-199 17679938-14 2007 CONCLUSIONS: This study demonstrates that by acting through CB2 receptors, the CB2-selective cannabinoid agonist JWH015 modulates the TM cell actin"s cytoskeleton and migration. JHW 015 113-119 cannabinoid receptor 2 Homo sapiens 60-63 17679938-14 2007 CONCLUSIONS: This study demonstrates that by acting through CB2 receptors, the CB2-selective cannabinoid agonist JWH015 modulates the TM cell actin"s cytoskeleton and migration. JHW 015 113-119 cannabinoid receptor 2 Homo sapiens 79-82 17185040-0 2007 CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. JHW 015 34-41 cannabinoid receptor 2 Homo sapiens 98-101 17185040-3 2007 In this study, we investigated the immunosuppressive properties of JWH-015, a synthetic CB2-selective agonist. JHW 015 67-74 cannabinoid receptor 2 Homo sapiens 88-91 17356307-8 2006 The effect of direct CB2 antisense oligonucleotide injection into the brain and treatment with JWH015 in motor function and plus-maze tests also demonstrated the functional presence of CB2 cannabinoid receptors in the central nervous system. JHW 015 95-101 cannabinoid receptor 2 Homo sapiens 185-188 16513651-3 2006 Upon stimulation with either of the CB2 ligands JWH015 and 2-arachidonoylglycerol (2-AG), neutrophil-like HL60 cells rapidly extended and retracted one or more pseudopods containing F-actin in different directions instead of developing front/rear polarity typically exhibited by migrating leukocytes. JHW 015 48-54 cannabinoid receptor 2 Homo sapiens 36-39 17183590-3 2007 The present study investigated the effects of the cannabinoid receptor 2 (CB2) ligand JWH-015 on cisplatin-induced apoptosis. JHW 015 86-93 cannabinoid receptor 2 Homo sapiens 74-77 17157480-10 2007 The selective CB2 receptor agonists JWH015 and BML190 elicited only partial inhibition, the non-selective CB agonist HU210 produced a concentration-dependent response, the activity of theses agonists were not blocked by either CB1/CB2 antagonists. JHW 015 36-42 cannabinoid receptor 2 Homo sapiens 14-17 16955257-0 2006 Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. JHW 015 42-49 cannabinoid receptor 2 Homo sapiens 120-123 15993070-1 2005 In silico modelling was used to guide the positioning of the fluorescent dye NBD-F on the cannabinoid CB2 receptor agonist JWH-015. JHW 015 123-130 cannabinoid receptor 2 Homo sapiens 102-105 16343349-7 2005 RESULTS: We found that the selective stimulation of cannabinoid receptor CB2 by JWH-015 suppressed IFN-gamma-induced CD40 expression. JHW 015 80-87 cannabinoid receptor 2 Homo sapiens 73-76 16343349-10 2005 Finally, we showed that CB2 activation by JWH-015 markedly attenuated CD40-mediated inhibition of microglial phagocytosis of Abeta1-42 peptide. JHW 015 42-49 cannabinoid receptor 2 Homo sapiens 24-27 12091357-6 2002 These human tumor cells were also susceptible to apoptosis induced by THC, HU-210, anandamide, and the CB2-selective agonist JWH-015. JHW 015 125-132 cannabinoid receptor 2 Homo sapiens 103-106 15914613-0 2005 CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. JHW 015 63-69 cannabinoid receptor 2 Homo sapiens 0-3 15914613-4 2005 RESULTS: The outflow facility was increased dose dependently within 1 hour after adding 10, 30, and 100 nM of JWH015, a CB2 agonist. JHW 015 110-116 cannabinoid receptor 2 Homo sapiens 120-123 15914613-5 2005 In addition, the effect of 100 nM of JWH015 was completely blocked by SR144528, a selective CB2 antagonist. JHW 015 37-43 cannabinoid receptor 2 Homo sapiens 92-95 15914613-10 2005 CONCLUSIONS: The data from this study demonstrate that the CB2-selective cannabinoid agonist JWH015 increases aqueous humor outflow facility. JHW 015 93-99 cannabinoid receptor 2 Homo sapiens 59-62 12813001-7 2003 3 The selective CB2 receptor ligands JWH-015 and indomethacin morpholinylamide (BML-190), when added to THP-1 cells before stimulation with lipopolysaccharide (LPS) and IFN-gamma, reduced the toxicity of their culture supernatants to SH-SY5Y cells. JHW 015 37-44 cannabinoid receptor 2 Homo sapiens 16-19 12813001-9 2003 The antineurotoxic activity of JWH-015 was blocked by the selective CB2 receptor antagonist SR144528, but not by the CB1 receptor antagonist SR141716A. JHW 015 31-38 cannabinoid receptor 2 Homo sapiens 68-71